Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06305390
Overview
This project aims to evaluate the role of fully hybrid PET/MRI with 18FPSMA and multiparametric MR imaging (mpMRI) as one-stop approach for the diagnosis of clinically significant prostate cancer (csPCa). Our main hypothesis is that adding 18F-PSMA PET to mpMRI prior to biopsy, will reduce the number of false negative findings, while at the same time, allowing also to reduce the number of unnecessary prostate biopsies in patients with low-risk, clinically indolent PCa.
Sponsor
IRCCS San Raffaele
Phase
Phase 2
Contacts
Maria Picchio, MD
picchio.maria@hsr.it
02-26436117
Rachele Di Donato, PhD
didonato.rachele@hsr.it
02-26433639
ClinicalTrials.gov
NCT06305390Drug / Compound
Help us improve your experience